Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
1. An isolated polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:121, SEQ ID NO:49, and SEQ ID NO:51.
2. An isolated polypeptide comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of: N30R, Y32W, N34G, N50T, T51A, N52S, N53S, T56S, and F94Y.
3. An antigen binding molecule that specifically binds EGFR, comprising:
a heavy chain variable domain comprising:
(a) a CDR1 selected from the group consisting of: SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:123, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:125;
(b) the CDR2 of SEQ ID NO:79;
(c) the CDR3 of SEQ ID NO:107; and
a light chain variable domain comprising:
(a) the CDR1 of SEQ ID NO:111 or SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
4. The antigen binding molecule of claim 3 , wherein:
the heavy chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:59 or SEQ ID NO:65;
(b) the CDR2 of SEQ ID NO:79;
(c) the CDR3 of SEQ ID NO:107; and
the light chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
5. An antigen binding molecule that specifically binds EGFR, comprising:
a heavy chain variable domain comprising:
(a) a CDR1 selected from the group consisting of: SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:123, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:125;
(b) a CDR2 selected from the group consisting of: SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:127, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, and SEQ ID NO:105;
(c) the CDR3 of SEQ ID NO:107; and
a light chain variable domain comprising:
(a) the CDR1 of SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
6. The antigen binding molecule of claim 5 , wherein:
the heavy chain variable domain comprises:
(a) a CDR1 selected from the group consisting of: SEQ ID NO:53, SEQ ID NO:59, and SEQ ID NO:65;
(b) the CDR2 of SEQ ID NO:91 or SEQ ID NO:97;
(c) the CDR3 of SEQ ID NO:107; and
the light chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
7. The antigen binding molecule of claim 5 , wherein:
the heavy chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:59;
(b) the CDR2 of SEQ ID NO:91;
(c) the CDR3 of SEQ ID NO:107; and
the light chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
8. The antigen binding molecule of claim 5 , wherein:
the heavy chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:65;
(b) the CDR2 of SEQ ID NO:97;
(c) the CDR3 of SEQ ID NO:107; and
the light chain variable domain comprises:
(a) the CDR1 of SEQ ID NO:113;
(b) the CDR2 of SEQ ID NO:115; and
(c) the CDR3 of SEQ ID NO:117.
9. An antigen binding molecule that specifically binds EGFR, comprising:
a heavy chain variable domain comprising a sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:121, and
a light chain variable domain comprising the sequence of SEQ ID NO:43.
10. An antigen binding molecule that specifically binds EGFR, comprising:
(a) a heavy chain variable domain comprising a sequence selected from the group consisting of: SEQ ID No:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:121, and
(b)(1) a light chain variable domain comprising a sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:49, and SEQ ID NO:51, or
(b)(2) a light chain variable domain comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of: N30R, Y32W, N34G, N50T, T51A, N52S, N53S, T56S, and F94Y.
11. An antigen binding molecule that specifically binds EGFR, comprising:
(a) a heavy chain variable domain comprising the sequence of SEQ ID NO:15, and
(b)(1) a light chain variable domain comprising a sequence selected from the group consisting of: SEQ ID NO:43, SEQ ID NO:49, and SEQ ID NO:51, or
(b)(2) a light chain variable domain comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of: N30R, Y32W, N34G, N50T, T51A, N52S, N53S, T56S, and F94Y.
12. The antigen binding molecule of claim 3 , wherein the antigen binding molecule is an antibody.
13. The antigen binding molecule of claim 3 , wherein the antigen binding molecule is an antibody fragment.
14. The antigen binding molecule of claim 13 , wherein the antibody fragment is selected from the group consisting of an scFv fragment, an Fv fragment, an F(ab′)2 fragment, a minibody, a diabody, a triabody, and a tetrabody.
15. The antigen binding molecule of claim 3 , wherein the antigen binding molecule comprises an Fc region.
16. The antigen binding molecule of claim 15 , wherein the Fc region is a human Fc region.
17. The antigen binding molecule of claim 16 , wherein the human Fc region is a human IgG Fc region.
18. The antigen binding molecule of claim 15 , wherein the antigen binding molecule has been glycoengineered to modify the oligosaccharides in the Fc region.
19. The antigen binding molecule of claim 18 , wherein the Fc region has a reduced number of fucose residues as compared to the nonglycoengineered antigen binding molecule.
20. The antigen binding molecule of claim 18 , wherein the glycoengineered antigen binding molecule has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to the nonglycoengineered antigen binding molecule.
21. The antigen binding molecule of claim 18 , wherein the Fc region has an increased proportion of bisected oligosaccharides as compared to the nonglycoengineered antigen binding molecule.
22. The antigen binding molecule of claim 18 , wherein the modified oligosaccharides are bisected complex.
23. The antigen binding molecule of claim 18 , wherein the modified oligosaccharides have an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of the antigen binding molecule compared to the nonglycoengineered antigen binding molecule.
24. The antigen binding molecule of claim 23 , wherein the bisected, nonfucosylated Oligosaccharides are hybrid.
25. The antigen binding molecule of claim 23 , wherein the bisected, nonfucosylated oligosaccharides are complex.
26. The antigen binding molecule of claim 18 , wherein the antigen binding molecule has increased effector function compared to the nonglycoengineered antigen binding molecule.
27. The antigen binding molecule of claim 26 , wherein the increased effector function is selected from the group consisting of: increased Fc-mediated cellular cytotoxicity, increased binding to NK cells, increased binding to macrophages, increased binding to monocytes, increased binding to polymorphonuclear cells, direct signaling inducing apoptosis, increased dendritic cell maturation, and increased T cell priming.
28. The antigen binding molecule of claim 18 , wherein the antigen binding molecule has increased Fc receptor binding compared to the nonglycoengineered antigen binding molecule.
29. The antigen binding molecule of claim 28 , wherein the Fc receptor is Fc activating receptor.
30. The antigen binding molecule of claim 28 , wherein the Fc receptor is FcγRIIIa receptor.
31. The antigen binding molecule of claim 18 , wherein at least 50% of the oligosaccharides in the Fc region are bisected.
32. The antigen binding molecule of claim 18 , wherein at least 70% of the oligosaccharides in the Fc region are bisected.
33. The antigen binding molecule of claim 18 , wherein at least 90% of the oligosaccharides in the Fc region are bisected.
34. The antigen binding molecule of claim 18 , wherein at least 50% of the oligosaccharides in the Fc region are nonfucosylated.
35. The antigen binding molecule of claim 18 , wherein at least 75% of the oligosaccharides in the Fc region are nonfucosylated.
36. The antigen binding molecule of claim 18 , wherein at least 90% of the oligosaccharides in the Fc region are nonfucosylated.
37. The antigen binding molecule of claim 18 , wherein at least 20% of the oligosaccharides in the Fc region are bisected, nonfucosylated.
38. The antigen binding molecule of claim 18 , wherein at least 35% of the oligosaccharides in the Fc region are bisected, nonfucosylated.
39. The antigen binding molecule of claim 18 , wherein at least 70% of the oligosaccharides in the Fc region are bisected, nonfucosylated.
40. The antigen binding molecule of claim 3 , wherein the antigen binding molecule, when administered to a mammalian subject at concentrations above one microgram per milliliter of serum, does not cause a clinically significant level of toxicity in the subject.
41. A composition comprising the antigen binding molecule according to claim 3 and a pharmaceutically acceptable carrier.
42. The composition of claim 41 , wherein the composition further comprises an adjuvant.
43. The antigen binding molecule of claim 3 , further comprising an Fc region engineered to have increased effector function or increased Fc receptor binding affinity, wherein the antigen binding molecule is produced by a method comprising:
(a) culturing a host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity under conditions which permit the production of the antigen binding molecule and the modification of the oligosaccharides present on the Fc region of the antigen binding molecule; and
(b) isolating the antigen binding molecule.
44. The antigen binding molecule of claim 43 , wherein the host cell is further engineered to express a nucleic acid encoding a polypeptide having mannosidase II activity.